Literature DB >> 27599629

Approach to the Treatment of Diabetic Ketoacidosis.

Kamel S Kamel1, Martin Schreiber2, Ana P C P Carlotti3, Mitchell L Halperin4.   

Abstract

Diabetic ketoacidosis (DKA), a common cause of severe metabolic acidosis, remains a life-threatening condition due to complications of both the disease and its treatment. This Acid-Base and Electrolyte Teaching Case discusses DKA management, emphasizing complications of treatment. Because cerebral edema is the most common cause of mortality and morbidity, especially in children with DKA, we emphasize its pathophysiology and implications for therapy. The risk for cerebral edema may be minimized by avoiding a bolus of insulin, excessive saline resuscitation, and a decrease in effective plasma osmolality early in treatment. A goal of fluid therapy is to lower muscle venous Pco2 to ensure effective removal of hydrogen ions by bicarbonate buffer in muscle and diminish the binding of hydrogen ions to intracellular proteins in vital organs (such as the brain). In patients with DKA and a relatively low plasma potassium level, insulin administration may cause hypokalemia and cardiac arrhythmias. It is suggested in these cases to temporarily delay insulin administration and first administer potassium chloride intravenously to bring the plasma potassium level close to 4mmol/L. Sodium bicarbonate administration in adult patients should be individualized. We suggest it be considered in a subset of patients with moderately severe acidemia (pH<7.20 and plasma bicarbonate level < 12mmol/L) who are at risk for worsening acidemia, particularly if hemodynamically unstable. Sodium bicarbonate should not be administered to children with DKA, except if acidemia is very severe and hemodynamic instability is refractory to saline administration.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetic ketoacidosis (DKA); acidemia; cerebral edema; hypokalemia; metabolic acidosis; type 1 diabetes mellitus (T1DM)

Mesh:

Substances:

Year:  2016        PMID: 27599629     DOI: 10.1053/j.ajkd.2016.05.034

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Central Pontine Myelinolysis in Pediatric Diabetic Ketoacidosis.

Authors:  Hannah Kinoshita; Leon Grant; Konstantine Xoinis; Prashant J Purohit
Journal:  Case Rep Crit Care       Date:  2018-06-04

2.  MERS-CoV Confirmation among 6,873 suspected persons and relevant Epidemiologic and Clinical Features, Saudi Arabia - 2014 to 2019.

Authors:  Shahul H Ebrahim; Andrew D Maher; Udhayashankar Kanagasabai; Sarah H Alfaraj; Nojom A Alzahrani; Saleh A Alqahtani; Abdullah M Assiri; Ziad A Memish
Journal:  EClinicalMedicine       Date:  2021-11-14

3.  Association between red blood cell distribution width and mortality in diabetic ketoacidosis.

Authors:  Huifang Dai; Xiaoyou Su; Hai Li; Lielie Zhu
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.